Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In Brief: Procept

Executive Summary

Procept: Initiates a program to develop new drugs for infectious diseases based on research in the CD-1 system of lipid antigen presentation conducted at Brigham & Women's Hospital and Harvard Medical School, the Cambridge, Mass.-based small molecule therapeutics company announces Jan. 10. Initial research will be done in the area of tuberculosis. To fund vaccine development, Procept, biotech execs and researchers joined in November to form VacTex, a financing vehicle that has raised $1 mil. Procept will have an ownership position in VacTex and an option to purchase the entire company...



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts